Skip to main content

Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer

Recruiting · Phase 3 · NCT06899126

Conditions: Non-small Cell Lung Cancer

At a glance

Research payments reported, 2025
$460,411
U.S. investigators named
15
Sites paid
19
Planned or actual enrollment
686

About the trial

Sponsor
Daiichi Sankyo (with Merck Sharp & Dohme LLC)
Tested
Trastuzumab Deruxtecan (drug), pembrolizumab (drug), Pemetrexed (drug), Platinum Chemotherapy (drug)
Dates
Started 2025-10-24; completion 2032-11-24
Results posted
Not yet

This clinical trial is designed to assess the efficacy and safety of trastuzumab deruxtecan (T-DXd; Enhertu®) in combination with pembrolizumab versus platinum-based chemotherapy in combination with pembrolizumab in participants with no prior therapy for locally advanced unresectable or metastatic non-squamous NSCLC, whose tumors have HER2-overexpressing and PD-L1 TPS \<50% without known AGA that have locally available therapies targeting their AGAs in first-line advanced/metastatic setting.

From ClinicalTrials.gov, last updated 2026-10-23. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Daiichi Sankyo Inc. reported $460,411 in research payments for this study in 2025 (870 payments).

Products named: Enhertu

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • Pro Research Tools, Inc $111,658
  • Ut MD Anderson Cancer Center $83,096
  • Brcr Global $48,436
  • Hope and Healing Cancer Services Hinsdale Office $43,921
  • Bay Pines VA Healthcare System $36,830
  • Clinical Research Alliance $29,502
  • Providence Medical Foundation $27,211
  • St Charles Medical Center - Bend, OR $23,581
  • Logan Health Medical Center, MT $19,894
  • California Research Institute $12,302
  • Alaska Oncology and Hematology $7,833
  • Holy Cross Hospital, FL $3,136
  • Gabrail Cancer Research Center $3,136
  • Los Angeles Hematology Oncology Medical Group $1,924
  • Los Angeles Cancer Network $1,821
  • First Health Cancer Center $1,821
  • Lumi Research $1,679
  • Orange Coast Memorial Medical Center $1,315
  • Mid Florida Cancer Centers-Orange City $1,315

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.